Biopharmaceutical companies are intensifying their focus on the development of products targeted to patient populations identified by particular genetic characteristics, and diagnostics companies are seeking opportunities to expand their libraries of genetic tests. These factors have led to the formation of an increasing number of companion diagnostic development and commercialization collaboration agreements.

In this webinar, a panel of WilmerHale attorneys and industry leaders discuss issues that commonly arise during the negotiation of such collaborations. Topics include typical deal structures; issues that commonly arise during negotiations; and competing interests of the parties to these transactions.

California and non-transitional New York CLE credit will be offered to those that participate in the live webinar.